Tirzepatide and GLP-1: The Dual GIP/GLP-1 Agonist

This guide belongs to the PlexusDx Education Hub, where we translate GLP-1 science, weight-management protocols, and the genetics of metabolism into plain language you can actually use.

Tirzepatide is often grouped with GLP-1 medications, but it is not a plain GLP-1 receptor agonist. Its defining feature is a dual mechanism that engages a second incretin receptor alongside the GLP-1 one. To understand why that matters, it helps to start with the natural hormone, then see how tirzepatide extends the design and where it sits in the timeline of approved compounds.

What native GLP-1 actually is

Native GLP-1 is a 30- to 31-amino-acid peptide secreted by intestinal L-cells in response to food. Once released, it stimulates glucose-dependent insulin secretion from pancreatic beta cells, suppresses glucagon, slows gastric emptying, and engages satiety circuits in the hypothalamus. Its half-life is only about 2 minutes, because the enzyme dipeptidyl peptidase-4 (DPP-4) degrades it rapidly.

How the receptor agonist class works

GLP-1 receptor agonist medications are engineered to resist DPP-4 degradation, extending half-life from minutes to days or weeks. They bind the same GLP-1 receptor as the native hormone, driving the same effects on insulin secretion, glucagon suppression, gastric emptying, and satiety. This is the shared backbone of the class before tirzepatide's extra receptor enters the picture.

Why tirzepatide is a dual agonist

Tirzepatide-based compounds add agonism at the GIP receptor, a related incretin receptor, on top of GLP-1 receptor activity. That dual engagement is one of the key molecular distinctions in the class as of April 2026, and it is why tirzepatide is described as a GIP/GLP-1 dual agonist rather than a single-receptor agonist.

The FDA approval timeline

The approved class spans exenatide (Byetta, 2005; Bydureon), liraglutide (Victoza, 2010; Saxenda, 2014), dulaglutide (Trulicity, 2014), semaglutide (Ozempic, 2017; Rybelsus, 2019; Wegovy, 2021), and tirzepatide (Mounjaro, 2022; Zepbound, 2023; Zepbound expanded to obstructive sleep apnea, 2024). Investigational compounds in late-stage development include the triple agonist retatrutide, which is not FDA-approved and not sold by PlexusDx, and the oral non-peptide agonist orforglipron.

Genetics of the incretin pathway

The incretin pathway carries natural genetic variation. GLP1R, the GLP-1 receptor gene itself, has variants that influence receptor density and downstream incretin signaling efficiency. FTO variants influence appetite regulation and adiposity set point, MC4R variants influence hypothalamic satiety signaling and total energy intake, and TCF7L2 variants influence insulin secretion and incretin response. These are pathway-level variables that describe the terrain any compound has to work on, and the Precision Peptide Genetic Test maps them across 14 pathways, 49 peptides, 150+ genetic insights. It does not predict response to any medication and is not a pharmacogenomic test.

Why the dual mechanism draws attention

The reason tirzepatide is discussed so intensely is that it recruits two incretin receptors rather than one. GIP and GLP-1 are both signals the gut releases after eating, and engaging both simultaneously is the molecular basis for classifying tirzepatide separately from single-receptor agonists. Trial programs such as SURPASS and SURMOUNT have studied this dual approach, and the data suggest the mechanism may produce larger mean effects on weight and glycemic control in some study populations. That is a statement about averages within trials, not a guarantee for any one person, which is precisely why upstream biology matters so much.

Why oral versus injectable comes up

Because these molecules are peptides vulnerable to enzymatic breakdown, most FDA-approved options are subcutaneous injections given weekly or daily by compound, and Rybelsus stands out as the only FDA-approved oral entry as of April 2026. Compounded oral protocols exist through licensed compounding pharmacy pathways but are not FDA-approved as branded products. Understanding that constraint explains why route of administration is a recurring question in this class and why the emergence of non-peptide oral candidates in development is considered a notable shift.

PlexusDx offers tirzepatide through its Weight Management Protocols. For brand context, see What Is Zepbound and Zepbound for Sleep Apnea.

Frequently Asked Questions

What does GLP-1 stand for?

GLP-1 stands for glucagon-like peptide-1, an incretin hormone secreted by intestinal L-cells in response to food. It stimulates glucose-dependent insulin release, slows gastric emptying, and signals satiety to the brain. The GLP-1 receptor agonist drug class mimics these effects pharmacologically at extended duration.

Are GLP-1 medications the same as GLP-1 inhibitors?

No, they are opposites. GLP-1 receptor agonists activate the receptor and reproduce the hormone's effects. There is no widely used class called "GLP-1 inhibitors" in current practice. DPP-4 inhibitors are separate; they reduce breakdown of native GLP-1 but do not activate the receptor directly.

How are these medications administered?

Most FDA-approved GLP-1 receptor agonists are given as subcutaneous injections, weekly or daily by compound. Rybelsus is the only FDA-approved oral option as of April 2026. Compounded oral protocols exist through licensed compounding pharmacy pathways and are not FDA-approved as branded products.

Does genetic testing tell me which GLP-1 to take?

No. The Precision Peptide Genetic Test does not determine which medication is right for anyone. It analyzes pathway-level variants in genes such as GLP1R, FTO, and MC4R that shape baseline GLP-1 biology, providing context for the broader protocol conversation with a healthcare provider rather than a recommendation.